Sigal Fatal - 14 Jun 2023 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role: Chief Financial Officer
Signature: /s/ David S. Glatt, Attorney-in-Fact for Sigal Fatal
Issuer symbol: CMMB
Transactions as of: 14 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2023, 16:03:05 UTC
Previous filing: 05 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CMMB	American Depositary Shares						5,209	14 Jun 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CMMB	Option to Purchase American Depositary Shares	Award	$0	+102,860	+158%	$0.000000	167,860	14 Jun 2023	American Depositary Shares	102,860	$1.70	Direct	F1, F3
transaction	CMMB	Option to Purchase American Depositary Shares	Award	$0	+29,400	+83%	$0.000000	65,000	08 Nov 2022	American Depositary Shares	29,400	$2.11	Direct	F1, F2, F4
transaction	CMMB	Option to Purchase American Depositary Shares	Award	$0	+35,600		$0.000000	35,600	11 Nov 2021	American Depositary Shares	35,600	$9.83	Direct	F1, F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2	No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this form 4 for informational purposes only.
F3	Options granted under the Company's 2017 Equity-Based Incentive Plan (the "Plan") on June 14, 2023; 25% of the options vest and become exercisable following 12 months from the grant thereof and an additional 6.25% vests at the end of each calendar quarter thereafter such that the options are fully vested and exercisable on June 14, 2027, subject to acceleration upon a change in control pursuant to the terms of the Option Agreement ("CIC") by and between the Reporting Person and the Issuer and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).
F4	These options vest and become exercisable pursuant to the following schedule: 25% of the options shall vest on November 8, 2023, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).
F5	These options vest and become exercisable pursuant to the following schedule: 25% of the options vested on November 11, 2022, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control pursuant ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).